Description

Balchem Corporation: How Are They Executing Margin Expansion Through Pricing and Supply Chain Flexibility? 

Balchem Corporation reported strong financial results for the first quarter of 2025, marked by record consolidated revenue, adjusted EBITDA, and adjusted net income. The company recorded $251 million in revenue, representing a 4.5% increase over the prior year, driven by growth in all three of its reporting segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Gross margin improved by 120 basis points to 35.2%, driven by a favorable product mix, while operating expenses declined by $3 million year-over-year due to lower amortization and compensation-related costs.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!